AbbVie Inc. with ticker code (ABBV) have now 24 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 193.34 and 127.32 calculating the mean target price we have $160.21. Given that the stocks previous close was at $146.31 and the analysts are correct then there would likely be a percentage uptick in value of 9.5%. The day 50 moving average is $149.21 and the 200 moving average now moves to $148.29. The market cap for the company is 256.39B. The stock price for the company is currently 145.26 USD
The potential market cap would be $280,749,274,830 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 29.83, revenue per share of 31.65 and a 9.18% return on assets.
AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.
